Last reviewed · How we verify
AIM Vaccine Co., Ltd. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
1 Phase 2
2 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| LVRNA009 | LVRNA009 | phase 3 | mRNA vaccine | Immunology/Oncology |
Therapeutic area mix
- Immunology/Oncology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Assistance Publique - Hôpitaux de Paris · 1 shared drug class
- BioNTech SE · 1 shared drug class
- CSPC Megalith Biopharmaceutical Co.,Ltd. · 1 shared drug class
- CanSino Biologics Inc. · 1 shared drug class
- Clover Biopharmaceuticals AUS Pty · 1 shared drug class
- Federal University of Espirito Santo · 1 shared drug class
- Jens D Lundgren, MD · 1 shared drug class
- Arcturus Therapeutics, Inc. · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for AIM Vaccine Co., Ltd.:
- AIM Vaccine Co., Ltd. pipeline updates — RSS
- AIM Vaccine Co., Ltd. pipeline updates — Atom
- AIM Vaccine Co., Ltd. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). AIM Vaccine Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/aim-vaccine-co-ltd. Accessed 2026-05-16.